With the FDA approval of PD-1 inhibitors for some gastrointestinal cancers [12], an increasing number of clinical trials on the use of PD-1/PD-L1 inhibitors have been conducted in the area of colorectal cancer. Here, CD274 is linked to colorectal cancer.